1. Biblio

Biblio

Found 3 results
Author Title Type [ Year(Asc)]
Filters: Author is Mologni, Luca  [Clear All Filters]
2019
G. G. Sharma, Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., Bidoli, P., Bisson, W. H., Pagni, F., Piazza, R., Gambacorti-Passerini, C., and Mologni, L., “A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib”, Journal of Thoracic Oncology, vol. 14, no. 11, pp. e257 - e259, 2019.
2014
S. Tardy, Orsato, A., Mologni, L., Bisson, W. H., Donadoni, C., Gambacorti-Passerini, C., Scapozza, L., Gueyrard, D., and Goekjian, P. G., “Synthesis and biological evaluation of benzo [4, 5] imidazo [1, 2-c] pyrimidine and benzo [4, 5] imidazo [1, 2-a] pyrazine derivatives as anaplastic lymphoma kinase inhibitors”, Bioorganic & medicinal chemistry, vol. 22, pp. 1303–1312, 2014.
2013
M. Ceccon, Mologni, L., Bisson, W. H., Scapozza, L., and Gambacorti-Passerini, C., “Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors”, Molecular Cancer Research, vol. 11, pp. 122–132, 2013.